144 related articles for article (PubMed ID: 7728765)
21. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
22. The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3.
Alper O; Yamaguchi K; Hitomi J; Honda S; Matsushima T; Abe K
Cell Growth Differ; 1990 Dec; 1(12):591-9. PubMed ID: 1981143
[TBL] [Abstract][Full Text] [Related]
23. Tyrosine phosphorylation at the membrane-microfilament interface: a p185neu-associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane- and microfilament-associated retroviral gag-like protein.
Juang SH; Carvajal ME; Whitney M; Liu Y; Carraway CA
Oncogene; 1996 Mar; 12(5):1033-42. PubMed ID: 8649794
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
25. Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer.
Di Modugno F; Buglioni S; Mottolese M; Bello DD; Cascioli S; Chersi A; Santoni A; Nisticò P
J Immunother; 2001; 24(3):221-31. PubMed ID: 11394499
[TBL] [Abstract][Full Text] [Related]
26. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.
Janes PW; Daly RJ; deFazio A; Sutherland RL
Oncogene; 1994 Dec; 9(12):3601-8. PubMed ID: 7970720
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical assay (IHC) to study C-erbB-2 status of breast cancer using monoclonal antibody CIBCgp185.
Meenakshi A; Kumar RS; Ganesh V; Sivakumar N
Hum Antibodies; 2003; 12(4):123-7. PubMed ID: 15156100
[TBL] [Abstract][Full Text] [Related]
28. Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody.
Flick MB; Sapi E; Perrotta PL; Maher MG; Halaban R; Carter D; Kacinski BM
Oncogene; 1997 May; 14(21):2553-61. PubMed ID: 9191055
[TBL] [Abstract][Full Text] [Related]
29. Basic science of HER-2/neu: a review.
Hung MC; Lau YK
Semin Oncol; 1999 Aug; 26(4 Suppl 12):51-9. PubMed ID: 10482194
[TBL] [Abstract][Full Text] [Related]
30. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
[TBL] [Abstract][Full Text] [Related]
31. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
32. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
33. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
34. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
Ram TG; Ethier SP
Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
[TBL] [Abstract][Full Text] [Related]
35. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.
Christianson TA; Doherty JK; Lin YJ; Ramsey EE; Holmes R; Keenan EJ; Clinton GM
Cancer Res; 1998 Nov; 58(22):5123-9. PubMed ID: 9823322
[TBL] [Abstract][Full Text] [Related]
36. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
[TBL] [Abstract][Full Text] [Related]
37. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression.
Wong LL; Chang CF; Koay ES; Zhang D
Int J Oncol; 2009 May; 34(5):1291-301. PubMed ID: 19360341
[TBL] [Abstract][Full Text] [Related]
39. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
[TBL] [Abstract][Full Text] [Related]
40. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.
Kang KS; Sun W; Nomata K; Morita I; Cruz A; Liu CJ; Trosko JE; Chang CC
Mol Carcinog; 1998 Apr; 21(4):225-33. PubMed ID: 9585252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
